Literature DB >> 28231626

Default mode network deactivation to smoking cue relative to food cue predicts treatment outcome in nicotine use disorder.

Claire E Wilcox1, Eric D Claus2, Vince D Calhoun2, Srinivas Rachakonda2, Rae A Littlewood2, Jessica Mickey2, Pamela B Arenella1, Natalie Goodreau2, Kent E Hutchison2,3.   

Abstract

Identifying predictors of treatment outcome for nicotine use disorders (NUDs) may help improve efficacy of established treatments, like varenicline. Brain reactivity to drug stimuli predicts relapse risk in nicotine and other substance use disorders in some studies. Activity in the default mode network (DMN) is affected by drug cues and other palatable cues, but its clinical significance is unclear. In this study, 143 individuals with NUD (male n = 91, ages 18-55 years) received a functional magnetic resonance imaging scan during a visual cue task during which they were presented with a series of smoking-related or food-related video clips prior to randomization to treatment with varenicline (n = 80) or placebo. Group independent components analysis was utilized to isolate the DMN, and temporal sorting was used to calculate the difference between the DMN blood-oxygen-level dependent signal during smoke cues and that during food cues for each individual. Food cues were associated with greater deactivation compared with smoke cues in the DMN. In correcting for baseline smoking and other clinical variables, which have been shown to be related to treatment outcome in previous work, a less positive Smoke - Food difference score predicted greater smoking at 6 and 12 weeks when both treatment groups were combined (P = 0.005, β = -0.766). An exploratory analysis of executive control and salience networks demonstrated that a more positive Smoke - Food difference score for executive control network predicted a more robust response to varenicline relative to placebo. These findings provide further support to theories that brain reactivity to palatable cues, and in particular in DMN, may have a direct clinical relevance in NUD.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  default mode network; functional MRI; nicotine use disorder; smoking; treatment outcome; varenicline

Mesh:

Substances:

Year:  2017        PMID: 28231626      PMCID: PMC5874131          DOI: 10.1111/adb.12498

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  44 in total

1.  Ten-year survival outcome of the nicotine transdermal patch with cognitive behavioural therapy.

Authors:  Robyn L Richmond; Linda Kehoe
Journal:  Aust N Z J Public Health       Date:  2007-06       Impact factor: 2.939

2.  Brain nicotinic acetylcholine receptor availability and response to smoking cessation treatment: a randomized trial.

Authors:  Arthur L Brody; Alexey G Mukhin; Michael S Mamoun; Trinh Luu; Meaghan Neary; Lidia Liang; Jennifer Shieh; Catherine A Sugar; Jed E Rose; Mark A Mandelkern
Journal:  JAMA Psychiatry       Date:  2014-07-01       Impact factor: 21.596

3.  Overlapping patterns of brain activation to food and cocaine cues in cocaine abusers: association to striatal D2/D3 receptors.

Authors:  Dardo Tomasi; Gene-Jack Wang; Ruiliang Wang; Elisabeth C Caparelli; Jean Logan; Nora D Volkow
Journal:  Hum Brain Mapp       Date:  2014-08-21       Impact factor: 5.038

4.  The effect of Varenicline on smoking cessation in a group of young asthma patients.

Authors:  Christian G Westergaard; Celeste Porsbjerg; Vibeke Backer
Journal:  Respir Med       Date:  2015-07-30       Impact factor: 3.415

5.  Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.

Authors:  H Rollema; L K Chambers; J W Coe; J Glowa; R S Hurst; L A Lebel; Y Lu; R S Mansbach; R J Mather; C C Rovetti; S B Sands; E Schaeffer; D W Schulz; F D Tingley; K E Williams
Journal:  Neuropharmacology       Date:  2006-12-08       Impact factor: 5.250

6.  Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial.

Authors:  H J Aubin; F Lebargy; I Berlin; C Bidaut-Mazel; J Chemali-Hudry; G Lagrue
Journal:  Addiction       Date:  2004-09       Impact factor: 6.526

7.  Predictors of 6-month tobacco abstinence among 1224 cigarette smokers treated for nicotine dependence.

Authors:  Jennifer A Ferguson; Christi A Patten; Darrell R Schroeder; Kenneth P Offord; Kay M Eberman; Richard D Hurt
Journal:  Addict Behav       Date:  2003-09       Impact factor: 3.913

8.  Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo.

Authors:  Rae A Littlewood; Eric D Claus; Claire E Wilcox; Jessica Mickey; Pamela B Arenella; Angela D Bryan; Kent E Hutchison
Journal:  Psychopharmacology (Berl)       Date:  2017-09-09       Impact factor: 4.530

9.  Interrater and intermethod reliability of default mode network selection.

Authors:  Alexandre R Franco; Aaron Pritchard; Vince D Calhoun; Andrew R Mayer
Journal:  Hum Brain Mapp       Date:  2009-07       Impact factor: 5.038

Review 10.  Efficacy of interventions to combat tobacco addiction: Cochrane update of 2013 reviews.

Authors:  Jamie Hartmann-Boyce; Lindsay F Stead; Kate Cahill; Tim Lancaster
Journal:  Addiction       Date:  2014-07-04       Impact factor: 6.526

View more
  5 in total

1.  Neural cue reactivity during acute abstinence predicts short-term smoking relapse.

Authors:  Cheyenne Allenby; Mary Falcone; E Paul Wileyto; Wen Cao; Leah Bernardo; Rebecca L Ashare; Amy Janes; James Loughead; Caryn Lerman
Journal:  Addict Biol       Date:  2019-02-25       Impact factor: 4.280

2.  Functional network connectivity predicts treatment outcome during treatment of nicotine use disorder.

Authors:  Claire E Wilcox; Vince D Calhoun; Srinivas Rachakonda; Eric D Claus; Rae A Littlewood; Jessica Mickey; Pamela B Arenella; Kent E Hutchison
Journal:  Psychiatry Res Neuroimaging       Date:  2017-04-30       Impact factor: 2.376

3.  Neurobiological Considerations for Tobacco Use Disorder.

Authors:  Megha Chawla; Kathleen A Garrison
Journal:  Curr Behav Neurosci Rep       Date:  2018-10-30

Review 4.  Alterations in resting-state functional connectivity in substance use disorders and treatment implications.

Authors:  Claire E Wilcox; Christopher C Abbott; Vince D Calhoun
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2018-06-25       Impact factor: 5.067

5.  Correlations Between the DMN and the Smoking Cessation Outcome of a Real-Time fMRI Neurofeedback Supported Exploratory Therapy Approach: Descriptive Statistics on Tobacco-Dependent Patients.

Authors:  Marco Paolini; Daniel Keeser; Boris-Stephan Rauchmann; Sarah Gschwendtner; Hannah Jeanty; Arne Reckenfelderbäumer; Omar Yaseen; Paul Reidler; Andrea Rabenstein; Hessel Jan Engelbregt; Maximilian Maywald; Janusch Blautzik; Birgit Ertl-Wagner; Oliver Pogarell; Tobias Rüther; Susanne Karch
Journal:  Clin EEG Neurosci       Date:  2021-12-08       Impact factor: 2.046

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.